top of page

Our CLINICAL TRIAL is now Recruiting Type 2 Diabetes Patients

Concenter Biopharma, together with the SHEBA Medical Center in Israel recently began recruiting patients for the clinical trial using the company's Zygosid-50 Drug. The Trial is examining the Safety and Efficacy of Zygosid-50 Administered by Sub-Cutaneous Injection for Glycemic Control of Patients with Type 2 Diabetes Mellitus.

Inclusion criteria in the trial include:

1.Male or female subjects with T2DM.

2.Age: 30 - 80 years.

3.10.5%>HbA1c >7.5%, and Hb>14 g/dl for men, and Hb>12 g/dl for women.

4.Stable diabetes treatment for the last 3 months.

5.Treatment with any anti-diabetic drugs except insulin.

6.BMI of 27 to 35 If you think you are interested in hearing more abbot the trial please contact our Chief Medical Officer - Prof. Amir Elami:

Information (Hebrew) from the Israeli Ministry of Health website:

Clinical Trials - GCP

SC Injection

2 comentarios

Zak Nor
Zak Nor
31 oct 2022

God bless you millions of people just pray for this till you guys find cures for us(diabetes)👏👏👏🙏🙏🙏

Me gusta

14 ago 2021

God bless

Me gusta
Logo concenter biopharma.jpg

Hi, thanks for stopping by!

Concenter BioPharma is a subsidiary of Silkim Pharma Ltd., which developed a novel, protected PLATFORM of drugs for proven treatments of multiple indications. 


Our PLATFORM is the result of extensive investigation of animal models of human diseases.

Let the news
come to you.

Thanks for submitting!

  • LinkedIn
  • Facebook
  • Twitter
bottom of page